CCLD
CareCloud, Inc.
CCLD's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over CCLD overall, supported by stronger fundamentals and lower modeled downside.
CCLD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
CCLD's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CCLD PE Valuation
CCLD has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CCLD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect CCLD's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over CCLD on the outlook, with more favorable revenue expectations.
CCLD Earnings Per Share
CCLD has returned to profit: it earned $0.13 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CCLD in the latest year-over-year earnings comparison.
CCLD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $33.7M | +8.6% |
| Q2 2026 | $31.9M | +16% |
| Q1 2026 | $31.3M | +13% |
| Q4 2025 | $34.4M | +22% |
| Q3 2025 | $31.1M | +8.8% |
| Q2 2025 | $27.4M | -2.5% |
| Q1 2025 | $27.6M | +6.4% |
| Q4 2024 | $28.2M | -0.6% |
CCLD's revenue has grown year over year for five quarters in a row: $34M last quarter, up 8.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +9.2 points |
| Q2 2026 | 5.8% | -5.1 points |
| Q1 2026 | 3.2% | -4.1 points |
| Q4 2025 | 9.1% | -3.2 points |
| Q3 2025 | 10% | -1.1 points |
| Q2 2025 | 11% | +2.9 points |
| Q1 2025 | 7.3% | +6.8 points |
| Q4 2024 | 12% | +166 points |
CCLD's operating margin was 20% last quarter, up 9.2 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CCLD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CCLD on profitability, with a higher operating margin.
CCLD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5.3M | -18% |
| Q2 2026 | $6.5M | +4.8% |
| Q1 2026 | $3.2M | -29% |
| Q4 2025 | $6.6M | +53% |
| Q3 2025 | $6.5M | -3.5% |
| Q2 2025 | $6.2M | +50% |
| Q1 2025 | $4.5M | +19% |
| Q4 2024 | $4.3M | +28% |
CCLD generated $22M in free cash flow over the past year, about the same as the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CCLD on cash flow, with more consistent year-over-year improvement.
CCLD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +56.4K shares |
| 1 year | +0.5% | +207K shares |
| 3 years | +181% | +27.4M shares |
| 5 years | +235% | +29.8M shares |
| Available history | +252% | +30.4M shares |
CCLD has 43M diluted shares, about the same as a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CCLD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CCLD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
CCLD has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CCLD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 48.9 | Neutral |
CCLD's weekly RSI is 58 (neutral) and its Stochastic is 49 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CCLD PE vs Healthcare Sector
| Metric | CCLD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CCLD has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CCLD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.05 | 29% above |
| 20 week MA | $2.23 | 18% above |
| 50 week MA | $2.55 | 3.5% above |
| 100 week MA | $2.63 | 0.4% above |
| 200 week MA | $2.44 | 8.2% above |
CCLD is in an uptrend: it's above all five of its weekly moving averages, and 8.2% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
CCLD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.15 | $9.37 | +126% |
| 2021 | $9.37 | $5.53 | -41% |
| 2022 | $5.53 | $2.85 | -48% |
| 2023 | $2.85 | $1.52 | -47% |
| 2024 | $1.52 | $3.64 | +139% |
| 2025 | $3.64 | $3.04 | -16% |
| 2026 YTD | $3.04 | $2.64 | -13% |
CCLD's yearly returns have swung widely, from +139% in 2024 to −48% in 2022. It's down 13% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CCLD on returns for 2026, with the stronger performance.